SecProbe.io

Filing text and metadata
Intelligence Terminal Search Topics Monthly Activity About

SEC Comment Letter 0000000000-26-006433 to PRF Technologies Ltd. (PRFX)

PRF Technologies Ltd.
Date: June 26, 2026 · CIK: 0001801834 · Accession: 0000000000-26-006433

Regulatory Compliance Offering / Registration Process

AI Filing Summary & Sentiment

Sentiment
Urgency
Document Type
Confidence
SEC Posture
Company Posture

Summary

Reasoning

File numbers found in text: 333-296943

Date
June 26, 2026
Author
Efraim Cohen-Arazi
Form
UPLOAD
Company
PRF Technologies Ltd.

Letter

June 26, 2026 Efraim Cohen-Arazi Interim Chief Executive Officer PRF Technologies Ltd. 65 Yigal Alon St. Tel Aviv 6744316, Israel Re: PRF Technologies Ltd. Registration Statement on Form F-1 Filed June 22, 2026 File No. 333-296943 Dear Efraim Cohen-Arazi: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Daniel Crawford at 202-551-7767 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences

Show Raw Text
June 26, 2026
Efraim Cohen-Arazi
Interim Chief Executive Officer
PRF Technologies Ltd.
65 Yigal Alon St.
Tel Aviv 6744316, Israel
Re: PRF Technologies Ltd.
Registration Statement on Form F-1
Filed June 22, 2026
File No. 333-296943
Dear Efraim Cohen-Arazi:
 This is to advise you that we have not reviewed and will not review your registration
statement.
 Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that
the company and its management are responsible for the accuracy and adequacy of their
disclosures, notwithstanding any review, comments, action or absence of action by the staff.
 Please contact Daniel Crawford at 202-551-7767 with any questions.
Sincerely,
Division of Corporation Finance
Office of Life Sciences